Methods of treating cancer with TNF expressing myxoma virus
AssigneeArizona Board of Regents on behalf of Arizona State University
InventorsDouglas Grant McFadden, John Christie, Joseph Blattman, Mohammed Masmudur Rahman, Nancy Yaneth Villa
Life of this patent
Estimating the term…
Abstract
Disclosed herein, in certain embodiments, is a method of inhibiting or treating a cancer with use of a TNF expressing myxoma virus. Also disclosed herein are methods of inhibiting or treating a cancer with use of a mononuclear peripheral blood cells and/or a bone marrow cells treated with a TNF-expressing myxoma virus. Some aspects relate to engineered myxoma virus and pharmaceutical compositions for use with one or more of the methods described herein.
Claims15
A pharmaceutical composition comprising a myxoma virus (MYXV) and a pharmaceutically-acceptable excipient, wherein the MYXV is engineered to express a tumor necrosis factor (TNF) protein, wherein a gene encoding the TNF protein is inserted between M134 gene and M136 gene within the MYXV genome.
A composition comprising peripheral blood mononuclear cells (PBMCs), bone marrow (BM) cells, or a combination thereof treated ex vivo by a myxoma virus (MYXV) engineered to express a tumor necrosis factor (TNF) protein, wherein a gene encoding the TNF protein is inserted between M134 gene and M136 gene within the MYXV genome.
A method of inhibiting or treating a cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a myxoma virus (MYXV) and a pharmaceutically-acceptable excipient, wherein the MYXV is engineered to express a tumor necrosis factor (TNF) protein, wherein a gene encoding the TNF protein is inserted between M134 gene and M136 gene within the MYXV genome.
Dependencies are inferred from the claim text.